Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20467320 | 1.00 | PTPN1 (0.42) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL6358667 | 1.00 | PTPN1 (0.42) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL22211568 | 1.00 | PTPN1 (0.42) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL10522832 | 0.87 | PTPN1 (0.48) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL3833437 | 0.87 | PTPN1 (0.48) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL13379049 | 0.87 | PTPN1 (0.48) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL6358553 | 0.87 | PTPN1 (0.45) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL22211395 | 0.86 | PTPN1 (0.44) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL500407 | 0.86 | PTPN1 (0.44) | PTPN1GBA1FUCA1DRD2RECQL | |
| SCHEMBL18453619 | 0.86 | PTPN1 (0.44) | PTPN1GBA1FUCA1DRD2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | INDIVIOR UK LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | PTPN1 2364/4885GBA1 2097/4885FUCA1 3798/4885 |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | PTPN1 2288/4885GBA1 2257/4885FUCA1 3806/4885 |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | DRD3, DRD2, OPRD1 | PTPN1 643/4885GBA1 3109/4885FUCA1 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.